Deucravacitinib
- Generic Name
- Deucravacitinib
- Brand Names
- Sotyktu
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O3
- CAS Number
- 1609392-27-9
- Unique Ingredient Identifier
- N0A21N6RAU
- Background
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved...
- Indication
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Tyrosine Kinase 2 (TYK2) for GA and CS
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT06725264
- Locations
- 🇺🇸
YCCI/Church Street Research Unit (CSRU), New Haven, Connecticut, United States
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
- Conditions
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 833
- Registration Number
- NCT06710470
- Locations
- 🇺🇸
Bristol-Meyers Squibb, Lawrenceville, New Jersey, United States
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT06701513
- Locations
- 🇫🇷
Hôpital Larrey, CHU Toulouse, Toulouse, France
Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT06566768
- Locations
- 🇬🇧
Local Institution - 0002, Nottingham, Nottinghamshire, United Kingdom
🇬🇧Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom
Deucravacitinib Rosacea
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 33
- Registration Number
- NCT06532136
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT06512337
- Locations
- 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China
🇨🇳Hangzhou Tigermed Consulting Co., Ltd., HangZhou, China
A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT06476834
- Locations
- 🇺🇸
Local Institution - 0001, Las Vegas, Nevada, United States
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT06444399
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06382987
- Locations
- 🇯🇵
Mebix. Inc., Minato-ku, Tokyo, Japan
🇯🇵Fukuoka University Hospital, Fukuoka, Japan
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 336
- Registration Number
- NCT06333860
- Locations
- 🇨🇦
Private Practice - Dr. Angelique Gagne-Henley /ID# 264267, St-Jérôme, Quebec, Canada
🇩🇪Universitaetsklinikum Freiburg /ID# 263069, Freiburg, Baden-Wuerttemberg, Germany
🇩🇪Beldio Research GmbH /ID# 263073, Memmingen, Bayern, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.